Tannock, I. F., de Vries, E. G. E., Fojo, A., Buyse, M., & Moja, L. (2025). Dose optimisation to improve access to effective cancer medicines. The Lancet Oncology, 26(3), e171–e180. https://doi.org/10.1016/s1470-2045(24)00648-x

Laothamatas, K., Benvenuto, L., Raval, M., Kim, F., Lemaitre, P. H., Sonett, J. R., & Arcasoy, S. M. (2025). Successful Lung Transplantation in A Patient With Pre-Existing Chronic Myeloid Leukemia Treated With Imatinib: A Case Report. Transplantation Proceedings, 57(3), 491–494. https://doi.org/10.1016/j.transproceed.2025.02.020

NAGINI, S., KALLAMADI, P. R., TANAGALA, K. K. K., & REDDY, G. B. (2024). Aldo-keto reductases: Role in cancer development and theranostics. Oncology Research, 32(8), 1287–1308. https://doi.org/10.32604/or.2024.049918

Rafic, E., Ma, C., Shih, B. B., Miller, H., Yuste, R., Palomero, T., & Etchenique, R. (2024). RuBi-Ruxolitinib: A Photoreleasable Antitumor JAK Inhibitor. Journal of the American Chemical Society, 146(19), 13317–13325. https://doi.org/10.1021/jacs.4c01720

Nadezhdin, K. D., Correia, L., Shalygin, A., Aktolun, M., Neuberger, A., Gudermann, T., Kurnikova, M. G., Chubanov, V., & Sobolevsky, A. I. (2024). Structural basis of selective TRPM7 inhibition by the anticancer agent CCT128930. Cell Reports, 43(4), 114108. https://doi.org/10.1016/j.celrep.2024.114108

Biard, L., Andrillon, A., Silva, R. B., & Lee, S. M. (2024). Dose optimization for cancer treatments with considerations for late-onset toxicities. Clinical Trials, 21(3), 322–330. https://doi.org/10.1177/17407745231221152

Wasko, U. N., Jiang, J., Dalton, T. C., Curiel-Garcia, A., Edwards, A. C., Wang, Y., Lee, B., Orlen, M., Tian, S., Stalnecker, C. A., Drizyte-Miller, K., Menard, M., Dilly, J., Sastra, S. A., Palermo, C. F., Hasselluhn, M. C., Decker-Farrell, A. R., Chang, S., Jiang, L., … Olive, K. P. (2024). Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature, 629(8013), 927–936. https://doi.org/10.1038/s41586-024-07379-z

Abou-Alfa, G. K., Geyer, S. M., Nixon, A. B., Innocenti, F., Shi, Q., Kumthekar, P., Jacobson, S., El Dika, I., Yaqubie, A., Lopez, J., Huang, B., Tang, Y.-W., Wen, Y., Schwartz, L. H., El-Khoueiry, A. B., Knox, J. J., Rajdev, L., Bertagnolli, M. M., Meyerhardt, J. A., … Venook, A. P. (2024). CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma. Cancer Research Communications, 4(3), 682–690. https://doi.org/10.1158/2767-9764.crc-22-0516

Wang, K., Du, R., Myall, N. J., Lewis, W. E., Uy, N., Hong, L., Skoulidis, F., Byers, L. A., Tsao, A., Cascone, T., Pozadzides, J., Tu, J., Negrao, M. V., Gibbons, D. L., Park, K., Rinsurongkawong, W., Lee, J. J., Gandara, D., Behl, D., … Le, X. (2024). Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 19(3), 500–506. https://doi.org/10.1016/j.jtho.2023.11.020

Brivio, E., Pennesi, E., Willemse, M. E., Huitema, A. D. R., Jiang, Y., van Tinteren, H. D. R., van der Velden, V. H. J., Beverloo, B. H., den Boer, M. L., Rammeloo, L. A. J., Hudson, C., Heerema, N., Kowalski, K., Zhao, H., Kuttschreuter, L., Bautista Sirvent, F. J., Bukowinski, A., Rizzari, C., Pollard, J., … Zwaan, C. M. (2024). Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921. Journal of Clinical Oncology, 42(7), 821–831. https://doi.org/10.1200/jco.23.00897

Yandamuri, S. S., Filipek, B., Lele, N., Cohen, I., Bennett, J. L., Nowak, R. J., Sotirchos, E. S., Longbrake, E. E., Mace, E. M., & O’Connor, K. C. (2024). A Noncanonical CD56dimCD16dim/− NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases. The Journal of Immunology, 212(5), 785–800. https://doi.org/10.4049/jimmunol.2300015

Cao, Q., Hajosch, A., Kast, R. E., Loehmann, C., Hlavac, M., Fischer-Posovszky, P., Strobel, H., Westhoff, M.-A., Siegelin, M. D., Wirtz, C. R., Halatsch, M.-E., & Karpel-Massler, G. (2024). Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British Journal of Cancer, 130(8), 1365–1376. https://doi.org/10.1038/s41416-024-02608-8

Cheng, X., Henick, B. S., & Cheng, K. (2024). Anticancer Therapy Targeting Cancer-Derived Extracellular Vesicles. ACS Nano, 18(9), 6748–6765. https://doi.org/10.1021/acsnano.3c06462

Chen, F., Tang, C., Yang, F., Ekpenyong, A., Qin, R., Xie, J., Momen-Heravi, F., Saba, N. F., & Teng, Y. (2024). HSP90 inhibition suppresses tumor glycolytic flux to potentiate the therapeutic efficacy of radiotherapy for head and neck cancer. Science Advances, 10(8). https://doi.org/10.1126/sciadv.adk3663

Maués, J., Loeser, A., Cowden, J., Johnson, S., Carlson, M., & Lee, S. (2024). The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing—Challenging the “more is better” dogma. Clinical Trials, 21(3), 358–362. https://doi.org/10.1177/17407745241232428

Mellgard, G. S., Fojo, T., & Bates, S. E. (2024). Lessons from withdrawn accelerated approvals in oncology. Nature Cancer, 5(2), 211–215. https://doi.org/10.1038/s43018-023-00696-8

Bloomhardt, H., Rubin, M., Xue, Y., Jin, Z., Masino, L., Seidel, D., Hijiya, N., & Beauchemin, M. (2024). Pediatric oncology provider perspectives and patient/family perceptions of chemotherapy‐induced nausea and vomiting management: Experiences at an academic medical center. Pediatric Blood & Cancer, 71(4). Portico. https://doi.org/10.1002/pbc.30883

Garralda, E., Schram, A. M., Bedard, P. L., Schwartz, G. K., Yuen, E., McNeely, S. C., Ribeiro, S., Cunningham, J., Wang, Y., Urunuela, A., Xu, X., & LoRusso, P. (2023). A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors. The Oncologist, 29(1), e131–e140. https://doi.org/10.1093/oncolo/oyad215

Banerjee, D., Boboila, S., Okochi, S., Angelastro, J. M., Kadenhe-Chiweshe, A. V., Lopez, G., Califano, A., Connolly, E. P., Greene, L. A., & Yamashiro, D. J. (2023). Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance. Cancer Research Communications, 3(12), 2518–2530. https://doi.org/10.1158/2767-9764.crc-23-0154

Hijiya, N., Maschan, A., Rizzari, C., Shimada, H., Dufour, C., Goto, H., Kang, H. J., Guinipero, T., Karakas, Z., Bautista, F., Ducassou, S., Yoo, K. H., Zwaan, C. M., Millot, F., Patterson, B. C., Samis, J., Izquierdo, M., Titorenko, K., Li, S., & Sosothikul, D. (2023). The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study. Blood Advances, 7(23), 7279–7289. https://doi.org/10.1182/bloodadvances.2023010122

Lichtenstein, M. R. L., Beauchemin, M. P., Raghunathan, R., Lee, S., Doshi, S. D., Law, C., Accordino, M. K., Elkin, E. B., Wright, J. D., & Hershman, D. L. (2024). Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs. JCO Oncology Practice, 20(1), 85–92. https://doi.org/10.1200/op.23.00205

Zeng, Y., Arisa, O., Peer, C. J., Fojo, A., & Figg, W. D. (2024). PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics. Seminars in Oncology, 51(1–2), 19–24. https://doi.org/10.1053/j.seminoncol.2023.09.005

Chakraborty, R., Milani, P., Palladini, G., & Gertz, M. (2023). Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies. The Lancet Haematology, 10(11), e936–e940. https://doi.org/10.1016/s2352-3026(23)00175-8

Liu, Y., Reiken, S., Dridi, H., Yuan, Q., Mohammad, K. S., Trivedi, T., Miotto, M. C., Wedderburn-Pugh, K., Sittenfeld, L., Kerley, Y., Meyer, J. A., Peters, J. S., Persohn, S. C., Bedwell, A. A., Figueiredo, L. L., Suresh, S., She, Y., Soni, R. K., Territo, P. R., … Guise, T. A. (2023). Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice. Science Translational Medicine, 15(715). https://doi.org/10.1126/scitranslmed.adf8977

Anderson, A., Rowles, W., Poole, S., Balan, A., Bevan, C., Brandstadter, R., Ciplea, A. I., Cooper, J., Fabian, M., Hale, T. W., Jacobs, D., Kakara, M., Krysko, K. M., Longbrake, E. E., Marcus, J., Repovic, P., Riley, C. S., Romeo, A. R., Rutatangwa, A., … Bove, R. (2023). Anti‐CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Annals of Clinical and Translational Neurology, 10(11), 2053–2064. Portico. https://doi.org/10.1002/acn3.51893

Tavares, L. M., de Jesus, L. C. L., Batista, V. L., Barroso, F. A. L., dos Santos Freitas, A., Campos, G. M., Américo, M. F., da Silva, T. F., Coelho-Rocha, N. D., Belo, G. A., Drumond, M. M., Mancha-Agresti, P., Vital, K. D., Fernandes, S. O. A., Cardoso, V. N., Birbrair, A., Ferreira, E., Martins, F. S., Laguna, J. G., & Azevedo, V. (2023). Synergistic synbiotic containing fructooligosaccharides and Lactobacillus delbrueckii CIDCA 133 alleviates chemotherapy-induced intestinal mucositis in mice. World Journal of Microbiology and Biotechnology, 39(9). https://doi.org/10.1007/s11274-023-03679-0

Suzuki, Y., Zhou, S., Ota, Y., Harrington, M., Miyagi, E., Takagi, H., Kuno, T., & Wright, J. D. (2023). Toxicity profiles of antibody-drug conjugates for anticancer treatment: a systematic review and meta-analysis. JNCI Cancer Spectrum, 7(5). https://doi.org/10.1093/jncics/pkad069

Viragova, S., Aparicio, L., Palmerini, P., Zhao, J., Valencia Salazar, L. E., Schurer, A., Dhuri, A., Sahoo, D., Moskaluk, C. A., Rabadan, R., & Dalerba, P. (2023). Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma. JNCI: Journal of the National Cancer Institute, 115(7), 838–852. https://doi.org/10.1093/jnci/djad062

Mato, A. R., Woyach, J. A., Brown, J. R., Ghia, P., Patel, K., Eyre, T. A., Munir, T., Lech-Maranda, E., Lamanna, N., Tam, C. S., Shah, N. N., Coombs, C. C., Ujjani, C. S., Fakhri, B., Cheah, C. Y., Patel, M. R., Alencar, A. J., Cohen, J. B., Gerson, J. N., … Jurczak, W. (2023). Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 389(1), 33–44. https://doi.org/10.1056/nejmoa2300696

Rimel, B. J., Crane, E. K., Hou, J., Nakayama, J., MacDonald, J., Lutz, K., Makker, V., & O’Cearbhaill, R. E. (2023). Tyrosine kinase inhibitor toxicities: A society of gynecologic oncology review and recommendations. Gynecologic Oncology, 174, 148–156. https://doi.org/10.1016/j.ygyno.2023.05.007

Shadman, M., Manzoor, B. S., Sail, K., Tuncer, H. H., Allan, J. N., Ujjani, C., Emechebe, N., Kamalakar, R., Coombs, C. C., Leslie, L., Barr, P. M., Brown, J. R., Eyre, T. A., Rampotas, A., Schuh, A., Lamanna, N., Skarbnik, A., Roeker, L. E., Bannerji, R., … Mato, A. R. (2023). Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical Lymphoma Myeloma and Leukemia, 23(7), 515–526. https://doi.org/10.1016/j.clml.2023.03.010

Ellingson, B. M., Wen, P. Y., Chang, S. M., van den Bent, M., Vogelbaum, M. A., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A. B., Gilbert, M. R., de Groot, J. F., Weller, M., Galanis, E., & Cloughesy, T. F. (2023). Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology, 25(6), 1017–1028. https://doi.org/10.1093/neuonc/noad002

Mundi, P. S., Dela Cruz, F. S., Grunn, A., Diolaiti, D., Mauguen, A., Rainey, A. R., Guillan, K., Siddiquee, A., You, D., Realubit, R., Karan, C., Ortiz, M. V., Douglass, E. F., Accordino, M., Mistretta, S., Brogan, F., Bruce, J. N., Caescu, C. I., Carvajal, R. D., … Califano, A. (2023). A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies. Cancer Discovery, 13(6), 1386–1407. https://doi.org/10.1158/2159-8290.cd-22-1020

Mair, M. J., Bartsch, R., Le Rhun, E., Berghoff, A. S., Brastianos, P. K., Cortes, J., Gan, H. K., Lin, N. U., Lassman, A. B., Wen, P. Y., Weller, M., van den Bent, M., & Preusser, M. (2023). Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nature Reviews Clinical Oncology, 20(6), 372–389. https://doi.org/10.1038/s41571-023-00756-z

Michel, A., Lee, R. T., Salehi, E., & Accordino, M. K. (2023). Improving Quality of Life During Chemotherapy: Cannabinoids, Cryotherapy, and Scalp Cooling. American Society of Clinical Oncology Educational Book, 43. https://doi.org/10.1200/edbk_390428

Lim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., Loffredo, J., Bandyopadhyay, N., Xie, H., & Hansen, A. R. (2023). Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 21(3), 366–375. https://doi.org/10.1016/j.clgc.2023.02.010

Kim, D.-W., Kim, S.-W., Camidge, D. R., Shu, C. A., Marrone, K. A., Le, X., Blakely, C. M., Park, K., Chang, G.-C., Patel, S. P., Kar, G., Cooper, Z. A., Samadani, R., Pluta, M., Kumar, R., & Ramalingam, S. (2023). CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology, 18(5), 650–656. https://doi.org/10.1016/j.jtho.2022.12.021

Ayaz, P., Lyczek, A., Paung, Y., Mingione, V. R., Iacob, R. E., de Waal, P. W., Engen, J. R., Seeliger, M. A., Shan, Y., & Shaw, D. E. (2023). Structural mechanism of a drug-binding process involving a large conformational change of the protein target. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-36956-5

LaRose, M., Connolly, R. M., O’Sullivan, C. C., Velcheti, V., Vilimas, R., Gano, K., Bates, S. E., Pommier, Y., & Thomas, A. (2023). A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. The Oncologist, 28(5), 460-e298. https://doi.org/10.1093/oncolo/oyad023

Gounder, M. M., Bauer, T. M., Schwartz, G. K., Weise, A. M., LoRusso, P., Kumar, P., Tao, B., Hong, Y., Patel, P., Lu, Y., Lesegretain, A., Tirunagaru, V. G., Xu, F., Doebele, R. C., & Hong, D. S. (2023). A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. Journal of Clinical Oncology, 41(9), 1714–1724. https://doi.org/10.1200/jco.22.01285

Fu, S., Yao, S., Yuan, Y., Previs, R. A., Elias, A. D., Carvajal, R. D., George, T. J., Yuan, Y., Yu, L., Westin, S. N., Xing, Y., Dumbrava, E. E., Karp, D. D., Piha-Paul, S. A., Tsimberidou, A. M., Ahnert, J. R., Takebe, N., Lu, K., Keyomarsi, K., & Meric-Bernstam, F. (2023). Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of Clinical Oncology, 41(9), 1725–1734. https://doi.org/10.1200/jco.22.00830

Tsai, C.-Y., Saito, T., Sarangdhar, M., Abu-El-Haija, M., Wen, L., Lee, B., Yu, M., Lipata, D. A., Manohar, M., Barakat, M. T., Contrepois, K., Tran, T. H., Theoret, Y., Bo, N., Ding, Y., Stevenson, K., Ladas, E. J., Silverman, L. B., Quadro, L., … Husain, S. Z. (2023). A systems approach points to a therapeutic role for retinoids in asparaginase-associated pancreatitis. Science Translational Medicine, 15(687). https://doi.org/10.1126/scitranslmed.abn2110

Guo, C., Figueiredo, I., Gurel, B., Neeb, A., Seed, G., Crespo, M., Carreira, S., Rekowski, J., Buroni, L., Welti, J., Bogdan, D., Gallagher, L., Sharp, A., Fenor de la Maza, M. D., Rescigno, P., Westaby, D., Chandran, K., Riisnaes, R., Ferreira, A., … de Bono, J. S. (2023). B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. European Urology, 83(3), 224–238. https://doi.org/10.1016/j.eururo.2022.09.004

Siddiqui, B. A., Chapin, B. F., Jindal, S., Duan, F., Basu, S., Yadav, S. S., Gu, A.-D., Espejo, A. B., Kinder, M., Pettaway, C. A., Ward, J. F., Tidwell, R. S. S., Troncoso, P., Corn, P. G., Logothetis, C. J., Knoblauch, R., Hutnick, N., Gottardis, M., Drake, C. G., … Subudhi, S. K. (2023). Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). Journal for ImmunoTherapy of Cancer, 11(3), e006262. https://doi.org/10.1136/jitc-2022-006262

Beauchemin, M. P., Lichtenstein, M. R. L., Raghunathan, R., Doshi, S. D., Lee, S., Law, C., Accordino, M. K., Elkin, E. B., Wright, J. D., & Hershman, D. L. (2023). Impact of a Hospital-Based Specialty Pharmacy in Partnership With a Care Coordination Organization on Time to Delivery and Receipt of Oral Anticancer Drugs. JCO Oncology Practice, 19(3), e326–e335. https://doi.org/10.1200/op.22.00451

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 388(4), 319–332. https://doi.org/10.1056/nejmoa2211582

Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., … Seymour, L. (2023). Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Annals of Oncology, 34(1), 48–60. https://doi.org/10.1016/j.annonc.2022.09.158

Lipsky, A. H., & Lamanna, N. (2022). Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia. Cancer, 129(1), 18–31. Portico. https://doi.org/10.1002/cncr.34510

Andrillon, A., Chevret, S., Lee, S. M., & Biard, L. (2022). Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression. Statistics in Medicine, 41(29), 5753–5766. Portico. https://doi.org/10.1002/sim.9591

Chaudhary, K. R., Kinslow, C. J., Cheng, H., Silva, J. M., Yu, J., Wang, Tony. J., Hei, T. K., Halmos, B., & Cheng, S. K. (2022). Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-14448-8